Vincent Fraipont
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Vincent Fraipont has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Christian Stoppe
Department of Anesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital Würzburg, Würzburg, Germany
2 shared publications François Damas
Department of Intensive Care, CHR Citadelle, Boulevard du 12ème de ligne 1, 4000 Liège, Belgium
2 shared publications- Albertus Beishuizen
Intensive Care Center, Medisch Spectrum Twente, Enschede, The Netherlands
1 shared publication Andrea Gabrio
Department of Methodology and Statistics, Maastricht University, Maastricht, the Netherlands
1 shared publication- Antoine Altdorfer
Department of Internal Medicine and Infectious Diseases, Centre Hospitalier Régional (CHR) de Liège, 4000 Liège, Belgium
1 shared publication - Arthur Raymond Hubert van Zanten
Department of Intensive Care Medicine & Research, Gelderse Vallei Hospital, Ede
1 shared publication
Latest Publications
- 1 July 2025
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 67 (7)
Wild Wild West
- 1 July 2025
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 67 (7)
Wild Wild West
- Open Access
- 29 January 2024
- Published by Elsevier in Annals of Intensive Care
- Vol. 14 (1) , 19-9
Clinical and molecular epidemiological features of critically ill patients with invasive group A Streptococcus infections: a Belgian multicenter case-series
- 29 January 2024
- Published by Elsevier in Annals of Intensive Care
- Vol. 14 (1) , 19-9
Open AccessClinical and molecular epidemiological features of critically ill patients with invasive group A Streptococcus infections: a Belgian multicenter case-series
- Open Access
- 10 November 2023
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 59, 162-170
The impact of high versus standard enteral protein provision on functional recovery following intensive care admission: Protocol for a pre-planned secondary Bayesian analysis of the PRECISe trial
- 10 November 2023
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 59, 162-170
Open AccessThe impact of high versus standard enteral protein provision on functional recovery following intensive care admission: Protocol for a pre-planned secondary Bayesian analysis of the PRECISe trial
- Open Access
- 10 September 2022
- Published by Springer Nature in Critical Care
- Vol. 26 (1) , 1-5
Clinical nutrition issues in 2022: What is missing to trust supplemental parenteral nutrition (SPN) in ICU patients?
A multidisciplinary group of international physicians involved in the medical nutrition therapy (MNT) of adult critically ill patients met to discuss the value, role, and open questions regarding supplemental parenteral nutrition (SPN) along with oral or enteral nutrition (EN), particularly in the intensive care unit (ICU) setting. This manuscript summarizes the discussions and results to highlight the importance of SPN as part of a comprehensive approach to MNT in critically ill adults and for researchers to generate new evidence based on well-powered randomized controlled trials (RCTs). The experts agreed on several key points: SPN has shown clinical benefits, resulting in this strategy being included in American and European guidelines. Nevertheless, its use is heterogeneous across European countries, due to the persistence of uncertainties, such as the optimal timing and the risk of overfeeding in absence of indirect calorimetry (IC), which results in divergent opinions and barriers to SPN implementation. Education is also insufficient. The experts agreed on actions needed to increase evidence quality on SPN use in specific patients at a given time point during acute critical illness or recovery.
- 10 September 2022
- Published by Springer Nature in Critical Care
- Vol. 26 (1) , 1-5
Open AccessClinical nutrition issues in 2022: What is missing to trust supplemental parenteral nutrition (SPN) in ICU patients?
A multidisciplinary group of international physicians involved in the medical nutrition therapy (MNT) of adult critically ill patients met to discuss the value, role, and open questions regarding supplemental parenteral nutrition (SPN) along with oral or enteral nutrition (EN), particularly in the intensive care unit (ICU) setting. This manuscript summarizes the discussions and results to highlight the importance of SPN as part of a comprehensive approach to MNT in critically ill adults and for researchers to generate new evidence based on well-powered randomized controlled trials (RCTs). The experts agreed on several key points: SPN has shown clinical benefits, resulting in this strategy being included in American and European guidelines. Nevertheless, its use is heterogeneous across European countries, due to the persistence of uncertainties, such as the optimal timing and the risk of overfeeding in absence of indirect calorimetry (IC), which results in divergent opinions and barriers to SPN implementation. Education is also insufficient. The experts agreed on actions needed to increase evidence quality on SPN use in specific patients at a given time point during acute critical illness or recovery.
- Open Access
Incidence and Risk Factors of COVID-19-Associated Pulmonary Aspergillosis in Intensive Care Unit—A Monocentric Retrospective Observational Study
Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is an increasingly recognized complication of COVID-19 and is associated with significant over-mortality. We performed a retrospective monocentric study in patients admitted to the intensive care unit (ICU) for respiratory insufficiency due to COVID-19 from March to December 2020, in order to evaluate the incidence of CAPA and the associated risk factors. We also analysed the diagnostic approach used in our medical centre for CAPA diagnosis. We defined CAPA using recently proposed consensus definitions based on clinical, radiological and microbiological criteria. Probable cases of CAPA occurred in 9 out of 141 patients included in the analysis (6.4%). All cases were diagnosed during the second wave of the pandemic. We observed a significantly higher realization rate of bronchoalveolar lavage (BAL) (51.1% vs. 28.6%, p = 0.01) and Aspergillus testing (through galactomannan, culture, PCR) on BAL samples during the second wave (p < 0.0001). The testing for Aspergillus in patients meeting the clinical and radiological criteria of CAPA increased between the two waves (p < 0.0001). In conclusion, we reported a low but likely underestimated incidence of CAPA in our population. A greater awareness and more systematic testing for Aspergillus are necessary to assess the real incidence and characteristics of CAPA.
Open AccessIncidence and Risk Factors of COVID-19-Associated Pulmonary Aspergillosis in Intensive Care Unit—A Monocentric Retrospective Observational Study
Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is an increasingly recognized complication of COVID-19 and is associated with significant over-mortality. We performed a retrospective monocentric study in patients admitted to the intensive care unit (ICU) for respiratory insufficiency due to COVID-19 from March to December 2020, in order to evaluate the incidence of CAPA and the associated risk factors. We also analysed the diagnostic approach used in our medical centre for CAPA diagnosis. We defined CAPA using recently proposed consensus definitions based on clinical, radiological and microbiological criteria. Probable cases of CAPA occurred in 9 out of 141 patients included in the analysis (6.4%). All cases were diagnosed during the second wave of the pandemic. We observed a significantly higher realization rate of bronchoalveolar lavage (BAL) (51.1% vs. 28.6%, p = 0.01) and Aspergillus testing (through galactomannan, culture, PCR) on BAL samples during the second wave (p < 0.0001). The testing for Aspergillus in patients meeting the clinical and radiological criteria of CAPA increased between the two waves (p < 0.0001). In conclusion, we reported a low but likely underestimated incidence of CAPA in our population. A greater awareness and more systematic testing for Aspergillus are necessary to assess the real incidence and characteristics of CAPA.
- Open Access
- 27 November 2013
- Published by Wiley in ISRN Nephrology
- Vol. 2013, 1-6
NGAL Usefulness in the Intensive Care Unit Three Hours after Cardiac Surgery
Objective. Neutrophil gelatinase-associated lipocalin (NGAL) measured by a research ELISA is described as an early marker of acute kidney injury (AKI). The aim of this study is to define the usefulness of plasma NGAL (pNGAL) and urine NGAL (uNGAL) measured with platform analysers to detect AKI 3 hours after cardiac surgery in fifty adult patients. Methods and Main Results. pNGAL and uNGAL were measured before and 3 hours after cardiac surgery. AKI, defined following the acute kidney injury network definition, was observed in 17 patients. pNGAL was >149 ng/mL in 8 patients with AKI, two of them died in the follow-up. We also observed elevated pNGAL in 8 patients without AKI. Only one uNGAL was >132 ng/mL among the 15 AKI patients. Sensitivity of pNGAL for prediction of AKI is 47% and specificity is 75.7%. The positive likelihood ratio (LR+) is 1.9 and negative likelihood ratio (LR−) is 0.7. uNGAL performance is slightly improved when reported to urinary creatinine. Following this study, a ratio >62 ng/mg assure a sensitivity of 66.6% and a specificity of 78.5%. LR+ is 3 and a LR− is, 0.42. Conclusions. Three hours after cardiac surgery, pNGAL predicts AKI with a low sensitivity and specificity.
- 27 November 2013
- Published by Wiley in ISRN Nephrology
- Vol. 2013, 1-6
Open AccessNGAL Usefulness in the Intensive Care Unit Three Hours after Cardiac Surgery
Objective. Neutrophil gelatinase-associated lipocalin (NGAL) measured by a research ELISA is described as an early marker of acute kidney injury (AKI). The aim of this study is to define the usefulness of plasma NGAL (pNGAL) and urine NGAL (uNGAL) measured with platform analysers to detect AKI 3 hours after cardiac surgery in fifty adult patients. Methods and Main Results. pNGAL and uNGAL were measured before and 3 hours after cardiac surgery. AKI, defined following the acute kidney injury network definition, was observed in 17 patients. pNGAL was >149 ng/mL in 8 patients with AKI, two of them died in the follow-up. We also observed elevated pNGAL in 8 patients without AKI. Only one uNGAL was >132 ng/mL among the 15 AKI patients. Sensitivity of pNGAL for prediction of AKI is 47% and specificity is 75.7%. The positive likelihood ratio (LR+) is 1.9 and negative likelihood ratio (LR−) is 0.7. uNGAL performance is slightly improved when reported to urinary creatinine. Following this study, a ratio >62 ng/mg assure a sensitivity of 66.6% and a specificity of 78.5%. LR+ is 3 and a LR− is, 0.42. Conclusions. Three hours after cardiac surgery, pNGAL predicts AKI with a low sensitivity and specificity.
- 1 July 2003
- Published by Elsevier in Annales Françaises d'Anesthésie et de Réanimation
- Vol. 22 (7) , 591-594
Intérêt d’un nomogramme fondé sur le poids et géré par l’infirmière pour adapter la posologie de l’héparine non fractionnée
- 1 July 2003
- Published by Elsevier in Annales Françaises d'Anesthésie et de Réanimation
- Vol. 22 (7) , 591-594
Intérêt d’un nomogramme fondé sur le poids et géré par l’infirmière pour adapter la posologie de l’héparine non fractionnée
- 24 January 2003
- Published by Springer Nature in Intensive Care Medicine
- Vol. 29 (3) , 507-508
Heart enlargement after thrombolysis for unsuccessful resuscitation
- 24 January 2003
- Published by Springer Nature in Intensive Care Medicine
- Vol. 29 (3) , 507-508
Heart enlargement after thrombolysis for unsuccessful resuscitation
- 1 March 2000
- Published by Wiley in Transfusion
- Vol. 40 (3) , 339-347
Successful mobilization of peripheral blood HPCs with G–CSF alone in patients failing to achieve sufficient numbers of CD34+ cells and/or CFU–GM with chemotherapy and G–CSF
BACKGROUND: Mobilization with chemotherapy and G–CSF may result in poor peripheral blood HPC collection, yielding 6 CD34+ cells per kg or 4 CFU–GM per kg in leukapheresis procedures. The best mobilization strategy for oncology patients remains unclear.STUDY DESIGN AND METHODS: In 27 patients who met either the CD34 (n = 3) or CFU–GM (n = 2) criteria or both (n = 22), the results obtained with two successive strategies—that is, chemotherapy and G–CSF at 10 μg per kg (Group 1, n = 7) and G–CSF at 10 μg per kg alone (Group 2, n = 20) used for a second mobilization course—were retrospectively analyzed. The patients had non‐Hodgkin's lymphoma (5), Hodgkin's disease (3), multiple myeloma (5), chronic myeloid leukemia (1), acute myeloid leukemia (1), breast cancer (6), or other solid tumors (6). Previous therapy consisted of 10 (1‐31) cycles of chemotherapy with additional chlorambucil (n = 3), interferon (n = 3), and radiotherapy (n = 7).RESULTS: The second collection was undertaken a median of 35 days after the first one. In Group 1, the results of the two mobilizations were identical. In Group 2, the number of CD34+ cells per kg per apheresis (0.17 [0.02‐0.45] vs. 0.44 [0.11‐0.45], p = 0.00002), as well as the number of CFU–GM (0.88 [0.00‐13.37] vs. 4.19 [0.96‐21.61], p = 0.00003), BFU–E (0.83 [0.00‐12.72] vs. 8.81 [1.38‐32.51], p = 0.00001), and CFU‐MIX (0.10 [0.00‐1.70] vs. 0.56 [0.00‐2.64], p = 0.001134) were significantly higher in the second peripheral blood HPC collection. However, yields per apheresis during the second collection did not significantly differ in the two groups. Six patients in Group 1 and 18 in Group 2 underwent transplantation, and all but one achieved engraftment, with a median of 15 versus 12 days to 1,000 neutrophils (NS), 22 versus 16 days to 1 percent reticulocytes (NS), and 26 versus 26 days to 20,000 platelets (NS), respectively. However, platelet engraftment was particularly delayed in many patients.CONCLUSION: G–CSF at 10 μg per kg alone may constitute a valid alternative to chemotherapy and G–CSF to obtain adequate numbers of peripheral blood HPCs in patients who previously failed to achieve mobilization with chemotherapy and G–CSF. This strategy should be tested in prospective randomized trials.
- 1 March 2000
- Published by Wiley in Transfusion
- Vol. 40 (3) , 339-347
Successful mobilization of peripheral blood HPCs with G–CSF alone in patients failing to achieve sufficient numbers of CD34+ cells and/or CFU–GM with chemotherapy and G–CSF
BACKGROUND: Mobilization with chemotherapy and G–CSF may result in poor peripheral blood HPC collection, yielding 6 CD34+ cells per kg or 4 CFU–GM per kg in leukapheresis procedures. The best mobilization strategy for oncology patients remains unclear.STUDY DESIGN AND METHODS: In 27 patients who met either the CD34 (n = 3) or CFU–GM (n = 2) criteria or both (n = 22), the results obtained with two successive strategies—that is, chemotherapy and G–CSF at 10 μg per kg (Group 1, n = 7) and G–CSF at 10 μg per kg alone (Group 2, n = 20) used for a second mobilization course—were retrospectively analyzed. The patients had non‐Hodgkin's lymphoma (5), Hodgkin's disease (3), multiple myeloma (5), chronic myeloid leukemia (1), acute myeloid leukemia (1), breast cancer (6), or other solid tumors (6). Previous therapy consisted of 10 (1‐31) cycles of chemotherapy with additional chlorambucil (n = 3), interferon (n = 3), and radiotherapy (n = 7).RESULTS: The second collection was undertaken a median of 35 days after the first one. In Group 1, the results of the two mobilizations were identical. In Group 2, the number of CD34+ cells per kg per apheresis (0.17 [0.02‐0.45] vs. 0.44 [0.11‐0.45], p = 0.00002), as well as the number of CFU–GM (0.88 [0.00‐13.37] vs. 4.19 [0.96‐21.61], p = 0.00003), BFU–E (0.83 [0.00‐12.72] vs. 8.81 [1.38‐32.51], p = 0.00001), and CFU‐MIX (0.10 [0.00‐1.70] vs. 0.56 [0.00‐2.64], p = 0.001134) were significantly higher in the second peripheral blood HPC collection. However, yields per apheresis during the second collection did not significantly differ in the two groups. Six patients in Group 1 and 18 in Group 2 underwent transplantation, and all but one achieved engraftment, with a median of 15 versus 12 days to 1,000 neutrophils (NS), 22 versus 16 days to 1 percent reticulocytes (NS), and 26 versus 26 days to 20,000 platelets (NS), respectively. However, platelet engraftment was particularly delayed in many patients.CONCLUSION: G–CSF at 10 μg per kg alone may constitute a valid alternative to chemotherapy and G–CSF to obtain adequate numbers of peripheral blood HPCs in patients who previously failed to achieve mobilization with chemotherapy and G–CSF. This strategy should be tested in prospective randomized trials.